New Standards for Care and Treatments Options Unveiled for Lymphoma

At the Annual Meeting of the American Society of Hematology, researchers will share new options for treating various lymphomas:

"The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress. Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable (referring to patients with clinical stage I or II disease and one or more risk factors) Hodgkin disease. Other research highlights the efficacy of an innovative investigational agent that has the potential to become a new treatment option for patients with relapsed or refractory Hodgkin disease, which currently has no available treatment options.

"Results of these studies underscore the continued progress we are making in improving the survival and quality of life of our patients with various forms of lymphoma," said Ginna G. Laport, MD, moderator of the press conference and Associate Professor of Medicine, Stanford University Medical Center. "Furthermore, these results represent another important step forward in finding a way to eradicate these particular forms of blood cancer."

This press conference will take place on Sunday, December 5, at 8:00 a.m.

An Intergroup Randomized Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis [Abstract 6]"

Read More: http://www.medilexicon.com/medicalnews.php?newsid=210464